5. Globalization of Clinical Trials: It Is Not Just About Slashing Costs
“If we really want to take advantage of global research, we need unified global regulatory requirements that are agnostic to where data is generated. If it is not sufficient for approval in markets that have high commercial value, the opportunity is limited.”
—Martina Flammer, MD, MBA, Senior Director, Emerging Markets, Pfizer, Inc.
Clinical Trials Take Up the Lion’s Share of Drug Development Costs
In the previous chapter, we saw how scientific research in both the public and private sectors has increasingly become a global enterprise. One of the ways the Western biopharma industry is seeking solutions to its R&D productivity crisis is by more internationalization of outsourcing. ...